Limited advances in therapy of glioblastoma trigger re-consideration of research policy

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 2, 2015, Pages 257-261

  Frosina, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bevacizumab; Bibliometrics; Glioma; Treatment protocol; Treatment quality

Indexed keywords

BEVACIZUMAB; LOMUSTINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CAUSE OF DEATH; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; MEDICAL LITERATURE; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREVALENCE; PROGRESSION FREE SURVIVAL; REVIEW; TIME TO TREATMENT; TREATMENT RESPONSE; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; METHODOLOGY; PROCEDURES; STANDARDS;

ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GLIOBLASTOMA; HUMANS; RESEARCH DESIGN; STANDARD OF CARE;

EID: 84955178929     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.013     Document Type: Review

References (22)

1. Faguer R., Tanguy J.Y., Rousseau A., Clavreul A., Menei P. Early presentation of primary glioblastoma. Neurochirurgie 2014, 60:188-193.
2. Grimm S.A., Pfiffner T.J. Anaplastic astrocytoma. Curr Treat Opt Neurol 2013, 15:302-315.
3. Emblem K.E., Mouridsen K., Bjornerud A., Farrar C.T., Jennings D., Borra R.J., et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 2013, 19:1178-1183.
4. Tanaka S., Louis D.N., Curry W.T., Batchelor T.T., Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol 2013, 10:14-26.
5. Gil-Gil M.J., Mesia C., Rey M., Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013, 7:123-135.
6. Gilbert M.R. On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success. Curr Oncol Rep 2013, 15:24-26.
7. Alexander B.M., Wen P.Y., Trippa L., Reardon D.A., Yung W.K., Parmigiani G., et al. Biomarker-based adaptive trials for patients with glioblastoma - lessons from I-SPY 2. Neuro Oncol 2013, 15:972-978.
8. Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
9. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708.
10. Khasraw M., Ameratunga M., Grommes C. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opin Biol Ther 2014, 14:729-740.
11. Stupp R., Weller M. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro Oncol 2014, 16:765-767.
12. Crocetti E., Trama A., Stiller C., Caldarella A., Soffietti R., Jaal J., et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 2012, 48:1532-1542. RARECARE working group.
13. Yin A.A., Cheng J.X., Zhang X., Liu B.L. The treatment of glioblastomas: a systematic update on clinical phase III trials. Crit Rev Oncol Hematol 2013, 87:265-282.
14. Vecchio D., Daga A., Carra E., Marubbi D., Raso A., Mascelli S., et al. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019. Int J Cancer 2015, 136:1445-1457.
15. Wong E.T., Gautam S., Malchow C., Lun M., Pan E., Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw 2011, 9:403-407.
16. MacDonald T.J., Vezina G., Stewart C.F., Turner D., Pierson C.R., Chen L., et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the children's oncology group. Neuro Oncol 2013, 15:1438-1444.
17. Sampson J.H., Aldape K.D., Archer G.E., Coan A., Desjardins A., Friedman A.H., et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011, 13:324-333.
18. Corallo A.N., Croxford R., Goodman D.C., Bryan E.L., Srivastava D., Stukel T.A. A systematic review of medical practice variation in OECD countries. Health Policy 2014, 114:5-14.
19. Chowdhary S., Chamberlain M. Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother 2013, 13:937-949.
20. Grant J., Cottrell R., Cluzeau F., Fawcett G. Evaluating "payback" on biomedical research from papers cited in clinical guidelines: applied bibliometric study. BMJ 2000, 320:1107-1111.
21. Thompson D.F., Callen E.C., Nahata M.C. New indices in scholarship assessment. Am J Pharm Educ 2009, 73:111.
22. Piao Y., Liang J., Holmes L., Henry V., Sulman E., de Groot J.F. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013, 19:4392-4403.